Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Linda G. Apuzzo"'
Autor:
Joseph B. Margolick, Joel N. Blankson, Hejab Imteyaz, Susan Langan, Christine M. Durand, Karen A. O'Connell, Aima A. Ahonkhai, Christina M. Ceccato, Linda G. Apuzzo, Thomas M. Williams
Publikováno v:
AIDS. 24:2405-2408
We studied viral evolution in five human leukocyte antigen (HLA)-B*57 patients recently infected with HIV-1. Escape mutations in HLA-B*57-restricted Gag epitopes were present at study entry in all patients, but were not associated with significant in
Autor:
Jason B. Dinoso, Hejab Imteyaz, Joel E. Gallant, Susan Langan, Janet D. Siliciano, Joseph B. Margolick, Joel N. Blankson, Tricia L. Nilles, Linda G. Apuzzo, Kendall A. Smith
Publikováno v:
AIDS. 24:932-935
Interleukin (IL)-2 has been studied as a treatment for HIV infection because it stimulates the proliferation of T cells and augments antiviral immune functions [1,2]. Two regimens have been used: intermittent IL-2 (5 days every 8 weeks, usually 4.5
Autor:
Robert F. Siliciano, Stuart C. Ray, Joseph B. Margolick, Joel N. Blankson, Hejab Imteyaz, Karen A. O'Connell, Jie Xu, Linda G. Apuzzo, Anna P. Durbin, Thomas M. Williams
Publikováno v:
The Journal of Infectious Diseases. 200:1820-1824
The human immunodeficiency virus type 1 (HIV-1)-specific immune responses of patients with the HLA-B*57/5801 alleles who spontaneously control viral replication serve as an important model for T cell-based HIV-1 vaccines. Determining the breadth of t
Autor:
Christopher S. Fraser, Anita Rachlis, Kenneth Kasper, Joseph B. Margolick, Brian Conway, Phillippe El-Helou, Cécile Tremblay, Mona Loutfy, Joel E. Gallant, Linda G. Apuzzo, Joel Singer, Terry Lee, Harout Tossonian, Hubert Wong
Publikováno v:
PLoS ONE, Vol 10, Iss 11, p e0143259 (2015)
PLoS ONE
PLoS ONE
Background It has been proposed that initiation of antiretroviral treatment (ART) very soon after establishment of HIV infection may be beneficial by improving host control of HIV replication and delaying disease progression. Methods People with docu
Autor:
Scott Barnett, Craig W. Hendrix, Joel E. Gallant, J. Brooks Jackson, Fayez M. Hamzeh, Estelle Piwowar-Manning, Charles Raines, Linda G. Apuzzo
Publikováno v:
AIDS. 17:547-553
Objective: To evaluate the safety, tolerability, and trough levels of three pre-exposure prophylaxis regimens of nevirapine among HIV-1-uninfected subjects at high risk for HIV-1 infection. Methods: A phase I/II trial (HIVHOP 101) in which 33 such un
Autor:
Susan H. Eshleman, Carl O. Deetz, Eugene Sun, Charles Flexner, Ronald H. Lewis, Margo Heath-Chiozzi, Linda G. Apuzzo, Charles Raines, Joel E. Gallant, Cathy Fields, J. Brooks Jackson
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 25:322-328
Objective: To evaluate the safety, tolerability, and anti-HIV activity of ritonavir-nelfinavir (RTV-NFV). Design: Single-site, open-label, nonrandomized, multiple-dose trial of RTV combined with two doses of NFV in protease inhibitor (PI)-naive, HIV-
Autor:
Michael C. Smith, David V. Weinberg, Lee M. Jampol, Dorothy N. Friedberg, Kathleen Squires, L. Rickman, Allan H. Friedman, J. Hoffman, Janet L. Davis, Judith Feinberg, B. Martin, K. Tolson, Robert L. Murphy, K. Naughton, L. Eldred, Deborah Greenspan, C. Gerzack, J. O'Donell, R. Vandenbroucke, David J. Hardy, Victor Fainstein, R. Brookmeyer, M. A. Simanello, T. Flynn, John Bartlett, W. R. Freeman, C. R. Levine, M. Donithan, M. Stecens, T. J. Peterson, R. M. Webb, Steven A. Teich, Mark A. Jacobson, Linda G. Apuzzo, S. Chafey, T. Samo, M. D. Davis, J. I. Quiceno, H. Kachadoorian, P. Clogston, Y. I. Min, Henry S. Sacks, Jan A. Markowitz, J. Leslie, E. Chuang, J. M. Kline, J. Dodge, Stephen A. Spector, M. Agres-Segal, R. M. Owens, J. Brown-Bellamy, Alfred J. Saah, N. Justin, M. L. Van Natta, M. R. Isaacson, A. Irvine, N. Fink, C. LeCount, A. C. Klemm, H. Fall, D. J. Nowakowski, K. B. Collins, James P. Dunn, R. Franklin, K. Frost, J. Armstrong, S. Seiff, L. MacArthur-Chang, G. Peyman, S. Singer, Alice L. Sternberg, Curtis L. Meinert, L. Meixnert, R. King, L. C. Coleson, D. Dietrich, J. Larson, C. Severin, D. Henderly, P. Mendez, J. Brickbauer, Gary N. Holland, B. Polsky, S. Wise-Campbell, A. Addessi, M. Espinal, Tony W. Cheung, Richard Haubrich, C. Tuttle, R. Gross, B. J. Collison, A. M.K. Gilpin, Douglas A. Jabs, B. Barron, James Tonascia, R. Cheeseman, John W. Gittinger, R. A. Lewis
Publikováno v:
American Journal of Ophthalmology. 124:141-157
Autor:
John Bartlett, C. Tuttle, R. Gross, C. LeCount, J. Leslie, Douglas A. Jabs, T. Flynn, James P. Dunn, L. Merin, Linda G. Apuzzo, D. Greenspan, Richard A. Lewis, L. Eldred, R. King, Tobias Samo, Judith Feinberg, Victor Fainstein, P. Clogston, B. Barron
Publikováno v:
Controlled Clinical Trials. 13:22-39
Autor:
Linda G. Apuzzo, Karin Ernstrom, Brian Conway, Elizabeth Connick, Jean-Pierre Routy, Ann C. Collier, Florin Vaida, Bruce D. Walker, Martin Markowitz, Susan J. Little, Frederick Hecht, Joel E. Gallant, Joseph B. Margolick
Publikováno v:
Journal of acquired immune deficiency syndromes (1999). 50(3)
Background: Little is known about modifications to highly active antiretroviral therapy (HAART) initiated during acute or early HIV infection. Methods: Reasons for first modifications of HAART regimens were recorded using the AIDS Clinical Trials Gro
Autor:
Patricia Charache, Douglas A. Jabs, Linda G. Apuzzo, Michael Forman, James P. Dunn, Mathew W. MacCumber
Publikováno v:
American journal of ophthalmology. 119(5)
Purpose Resistance to antiviral therapy is a potential cause of progression of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. We investigated the results of viral sensitivity testing in a series of patients with cl